NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK

Sponsor
Hong Kong University of Science and Technology
Study ID
NCT07347574
Status
Recruiting
Apply to this trial

Conditions

  • AD - Alzheimer's Disease
  • Dementia
  • Mild Cognitive Impairment
  • Normal Cognition

Eligibility Criteria

Sex
ALL
Age
60 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Observational — OTHER
    Clinical profile, blood collection, cognitive assessment, MRI and PET imaging

Study Details

Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65. Given that aging is the primary risk factor for many common chronic diseases, reducing the burden of age-related illnesses and promoting healthy aging have become critical public health priorities. Notably, Hong Kong has one of the largest proportions of elderly and the highest life expectancy in the world. Dementia, particularly Alzheimer's disease (AD), is a multifaceted condition influenced by both biological and behavioral factors. There is a paucity of robust, community-based prospective data in ethnic Chinese populations that integrate clinical and cognitive measures with objective biomarkers and neuroimaging, especially at earlier stages such as mild cognitive impairment (MCI) and early AD. This community-based project aims to establish a cohort of elderly in Hong Kong, with longitudinal follow-up for 2-3 years. A key strength of this research is the incorporation of a panel of blood biomarkers, which will provide a less invasive and more affordable screening tool to identify Alzheimer's disease at a much earlier stage in the community. Additionally, through benchmark with MRI and PET imaging gold standard, these biomarkers have the potential to predict the conversion risk 1) from clinically normal to mild cognitive impairment and Alzheimer's disease (AD dementia); 2) from clinically MCI to Alzheimer's disease (MCI-AD dementia) or remain static; and differentiate non-AD dementia from Alzheimer's disease (dementia-AD). Collectively, these data will facilitate monitoring of aging processes and cognitive decline, help to identify candidate modifiable factors associated with resilience, and generate a de-identified, Chinese-specific resource to advance healthy aging in Hong Kong.

Key Dates

First listed
Jan 16, 2026
Start date
Mar 23, 2026
Status verified
Jan 2026
Primary completion
Dec 30, 2030
Completion
Dec 30, 2030

Study Design

Enrollment
2,500 participants (estimated)

Arms

  • Arm: Cognitively normal (CN)
    Participants with normal cognition
  • Arm: Mild cognitive impairment (MCI)
    Participants with MCI
  • Arm: Dementia
    Participants with dementia

Primary Outcome Measure

Blood biomarker (baseline) [ Time Frame: Baseline ]

Central Contacts

Related Studies